Results 101 to 110 of about 62,929 (228)

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

Nanoparticle polymeric micellar paclitaxel compared with paclitaxel for advanced esophageal squamous cell carcinoma

Precision Medical Sciences, EarlyView.
The nanoparticle polymeric micellar paclitaxel plus nedaplatin regimen demonstrates superior efficacy and tolerable toxicities compared to the paclitaxel–nedaplatin combination as a first‐line treatment for advanced esophageal squamous cell carcinoma.
Yu‐Qing Cao, Meng Song, Bing‐jie Xue, Fei‐Yu Wang, Xiang‐Ming Huang, Jie Cao, Ai‐Guo Cao, Xin‐En Huang   +7 more
wiley   +1 more source

RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment

Precision Medical Sciences, EarlyView.
This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run, Shiwei Jiang, Kun Xu, Yu Fan, Yanwen Chen, Ziao Liu, Zengli Miao, Wei Tian   +7 more
wiley   +1 more source

Variant Hypersensitivity Reaction (HSR) Presented with Persistent Dry Cough after Receiving Oxaliplatin in a Pancreatic Cancer Patient

Iranian Journal of Allergy, Asthma and Immunology, 2009
Oxaliplatin, a third generation of platinum-based anti-neoplastic agent has been approved for colorectal cancer in both adjuvant and metastatic settings.
Jia Li, Jennifer Peccerillo, Kristen Kaley   +2 more
doaj  

Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer

Scientific Reports
Oxaliplatin resistance remains a major challenge in colorectal cancer (CRC) treatment. We investigated the FBXL5/IREB2/TFRC axis in ferroptosis-mediated resistance reversal.
Miaomiao Wang, Ruizhe Zhang, Shuang He, Feifei Wen, Xiaojie Yu, Xiaoyang Xu, Yangyang Li, Shuhua Wu   +7 more
doaj   +1 more source

Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In advanced rectal cancer patients receiving total neoadjuvant therapy (TNT), overall tumor response did not differ by diabetes status or metformin use. However, among diabetic patients, metformin use was associated with higher overall complete response rates. These findings suggest a potential benefit of metformin in enhancing TNT response in diabetic
Sergei Bedrikovetski, Mahima Raju, Tracy Fitzsimmons, Ishraq Murshed, Timothy J. Price, Michael Penniment, Sudarsha Selva‐Nayagam, Tarik Sammour   +7 more
wiley   +1 more source

Benchmarked Colorectal Cancer Outcomes in a Metropolitan Hospital: A 5‐Year Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In metastatic disease, patients with lung‐only metastasis had the best 5‐year survival at 46.0% and curative‐intent approaches can dramatically improve survival. ABSTRACT Introduction Colorectal cancer (CRC) remains a major contributor to cancer‐related mortality worldwide, with survival influenced by many prognostic factors.
Jialin Du, Vincent Wang, Basil D'Souza, Russell Hodgson   +3 more
wiley   +1 more source

Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
There is limited understanding of the impact of underlying RAS/RAF mutational status on total neoadjuvant therapy metastatic tumor response rates in curative Stage IV rectal cancer patients. Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients and disease progression was higher in patients harboring RAS ...
Tracy R. Fitzsimmons, Z. Bunjo, E. L. Neo, A. Badiei, M. Penniment, S. Selva‐Nayagam, A. Ruszkiewicz, J. Wong, T. Sammour   +8 more
wiley   +1 more source

Two Decades of Multimodal Management of Colorectal Liver Metastases With Long‐Term Outcomes

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background The management of patients with colorectal liver metastases (CRLM) is complex and requires a tailored approach based on disease extent, patient age, and comorbidities. Given the heterogeneity in presentation and evolving treatment algorithms, prognostic factors for long‐term survival following liver resection are contested.
Ali Mohtashami, Prajwol Shrestha, Sharon Chen, Jean‐Luc Vrisakis, Nazim Bhimani, Nick Pavlakis, Stephen J. Clarke, Connie I. Diakos, Matthew Wong, Thomas J. Hugh   +9 more
wiley   +1 more source

Response‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort

British Journal of Haematology, EarlyView.
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff, Fabian Görke, Vanja Zeremski, Sophia Wollnitza, Evgenii Shumilov, Georg Lenz, Ellen Obstfelder, Inken Hilgendorf, Vladan Vučinić, Andreas Hochhaus, Ulf Schnetzke   +10 more
wiley   +1 more source